The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Nov. 26, 5:50 AM

Slide #23. Rockwell Medical, Inc. Secondary Offering

Company: Rockwell Medical, Inc. (NASDAQ:RMTI)
Date announced: 11/17/2014
Shares Offered: 6,500,000
Date of Pricing: 11/19/2014
Price Per Share: $9.00
Secondary Offering Details: Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today its intention to offer up to $55 million of its common shares in an underwritten public offering. Rockwell also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering. - updated 9/20 - Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today that it has priced an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $9.00 per share for gross proceeds of $58.5 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by Rockwell, will be approximately $54.7 million. Rockwell has also granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock offered in the public offering.

Rockwell Medical a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis (also referred to as dialysis). Co.'s primary investigational drug, Triferic®, also known as Soluble Ferric Pyrophosphate, delivers iron to the bone marrow in a non-invasive, physiologic manner to hemodialysis patients via dialysate during their regular dialysis treatment. In addition, Co. manufactures, sells, delivers and distributes hemodialysis concentrates, along with a line of ancillary products to customers in the U.S. and abroad.
Open the RMTI Page at The Online Investor »

Company Name:  Rockwell Medical, Inc
Sector:  Medical Instruments & Supplies
Number of ETFs Holding RMTI:  17
Total Market Value Held by ETFs:  $9.89M
Total Market Capitalization:  $393.00M
% of Market Cap. Held by ETFs:  2.52%
 

Open the RMTI Page at The Online Investor (in a new window) »

November 26, 2014    5:50 AM Eastern
Quotes delayed 20 minutes



Hold (2.00 out of 4)
1st percentile
(ranked lower than approx. 99% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.